10 research outputs found
Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013–2014 influenza season in Mainland China
Get PDFWatershed modeling for reducing future non-point source sediment and phosphorus load in the Lake Tana Basin, Ethiopia
No full textEpistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses
No full textImmune Escape Mutants of Highly Pathogenic Avian Influenza H5N1 Selected Using Polyclonal Sera: Identification of Key Amino Acids in the HA Protein
No full text
Resistance to influenza neuraminidase inhibitors
No full textAnnual epidemics and periodic pandemics caused by influenza viruses are associated with significant disease burden. Three classes of antiviral compounds, M2 ion-channel blockers (Amantadine and Rimantadine), neuraminidase (NA) inhibitors (Zanamivir, Oseltamivir, Peramivir, Laninamivir), and RNA-dependent RNA polymerase inhibitor (Favipiravir) have been approved for clinical use against influenza infections to date. The M2 ion-channel blockers effective in inhibiting proton conductivity of influenza A viruses were no longer recommended for clinical use since 2009 due to high prevalence of resistant variants among seasonal influenza A viruses of H3N2 and H1N1 subtypes. NA inhibitors are the current mainstays for influenza prophylaxis and treatment. Four approved NA inhibitors were structural-based designed to achieve specific interactions with the conserved residues at the NA enzyme site. This Chapter will discuss the resistance mechanisms for the NA inhibitors
